Intra-Cellular Therapies to Participate at Upcoming Investor Conferences
September 18 2017 - 8:00AM
Intra-Cellular Therapies, Inc. (Nasdaq:ITCI), a biopharmaceutical
company focused on the development of therapeutics for central
nervous system ("CNS") disorders, today announced it will
participate at the following investor conferences in September
2017:
- Cantor Fitzgerald Global Healthcare Conference taking place in
New York City from September 25-27, 2017. Sharon Mates, Ph.D.,
Chief Executive Officer and Chairman, is scheduled to present on
Monday, September 25, 2017 at 1:15 pm ET.
- Ladenburg Thalmann 2017 Healthcare Conference taking place in
New York City on September 26, 2017. Sharon Mates, Ph.D., Chief
Executive Officer and Chairman, is scheduled to present on Tuesday,
September 26, 2017 at 11:00 am ET.
The live and archived webcasts can be accessed under "Events
& Presentations" in the Investor Relations section of the
Company's website at www.intracellulartherapies.com. Please log in
approximately 5-10 minutes prior to the event to register and to
download and install any necessary software.
About Intra-Cellular Therapies
Intra-Cellular Therapies is developing novel drugs for the
treatment of neuropsychiatric and neurodegenerative diseases and
diseases of the elderly, including Parkinson's and Alzheimer's
disease. The Company is developing its lead drug candidate,
lumateperone (also known as ITI-007), for the treatment of
schizophrenia, bipolar disorder, behavioral disturbances in
patients with dementia, including Alzheimer's disease, depression
and other neuropsychiatric and neurological disorders.
Lumateperone, a first-in-class molecule, is in Phase 3 clinical
development for the treatment of schizophrenia, bipolar depression
and agitation associated with dementia, including Alzheimer's
disease. The Company is also utilizing its phosphodiesterase (PDE)
platform and other proprietary chemistry platforms to develop drugs
for the treatment of CNS and other disorders. The lead molecule in
the Company's PDE1 portfolio, ITI-214, is in development for the
treatment of symptoms associated with Parkinson's disease.
Contact:Juan Sanchez, M.D. Vice President
Corporate Communications and Investor Relations of Intra-Cellular
Therapies, Inc. Phone: 212-923-3344
Burns McClellan, Inc. Lisa Burns Justin Jackson
(Media)jjackson@burnsmc.com212-213-0006
Intra Cellular Therapies (NASDAQ:ITCI)
Historical Stock Chart
From Mar 2024 to Apr 2024
Intra Cellular Therapies (NASDAQ:ITCI)
Historical Stock Chart
From Apr 2023 to Apr 2024
